Skip to main content

Advertisement

Log in

Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

To examine the incorporation of anti-CCP antibodies into the American College of Rheumatology (ACR) classification criteria for rheumatoid arthritis (RA) and to evaluate the advantages of the revised anti-CCP criteria in diagnosing Chinese patients. Patients who suffered from arthritic problems during the recent 2 years were selected from the Department of Rheumatology and Immunology of Peking University People's Hospital. The patients were divided into RA group and non-RA group according to the clinical diagnosis by experienced rheumatologists. The ACR criteria were revised in three ways: (1) replacement of rheumatoid nodules and erosions as criteria with anti-CCP antibodies (RA-6 criteria); (2) replacement of rheumatoid nodules with anti-CCP antibodies as a criterion (RA-7 criteria); (3) addition of anti-CCP antibodies (RA-8 criteria). The diagnostic value of ACR criteria and anti-CCP revised criteria (RA-6, RA-7, and RA-8) were evaluated by comparing the sensitivity and specificity of all criteria, in all subjects and in subjects with arthritis symptoms within 2 years. There were 604 patients included in the study totally, among whom 312 patients were diagnosed as RA and 292 were diagnosed as other rheumatic diseases by rheumatologists. For all the RA patients, the sensitivity and specificity of anti-CCP antibodies were 76.2% and 96%, respectively. Its specificity was much higher than RF (85.2%). For the patients with a disease duration less than two years, the sensitivities were 82.0%, 91.0%, 87.0%, and 87.0%, while the specificities were 95.6%, 83.9%, 95.6%, and 95.6%, respectively, according to 1987 ACR criteria, RA-6, RA-7, and RA-8 criteria. Among all the RA patients, the corresponding sensitivities were 92.3%, 96.8%, 94.6%, and 94.6%, and the specificities were 92.8%, 83.6%, 92.8%, and 92.8%, respectively. The 1987 ACR criteria have high sensitivity and specificity in established RA, but are less sensitive in early RA. The RA-6 criteria improve the sensitivity by reducing its specificity. The RA-7 criteria with replacement of rheumatoid nodules by anti-CCP antibodies increase the sensitivity without losing specificity, which may serve as new classification criteria in routine clinical practice, especially in early RA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  CAS  PubMed  Google Scholar 

  2. Saraux A, Berthelot JM, Chales G et al (2001) Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44:2485–2491

    Article  CAS  PubMed  Google Scholar 

  3. Zendman AJ, Vossenaar ER, van Venrooij WJ (2004) Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 37:295–299

    Article  CAS  PubMed  Google Scholar 

  4. Liao KP, Batra KL, Chibnik L et al (2008) Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 67(11):1557–1561

    Article  CAS  PubMed  Google Scholar 

  5. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39:713–722

    Article  Google Scholar 

  6. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46:328–346

    Article  Google Scholar 

  7. Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784

    Article  CAS  PubMed  Google Scholar 

  8. Kaarela K, Kauppi MJ, Lehtinen KE (1995) The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 24:279–281

    Article  CAS  PubMed  Google Scholar 

  9. Aletaha D, Breedveld FC, Smolen JS (2005) The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum 52:3333–3336

    Article  PubMed  Google Scholar 

  10. Mathsson L, Mullazehi M, Wick MC et al (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45

    Article  CAS  PubMed  Google Scholar 

  11. Hill JA, Al-Bishri J, Gladman DD et al (2006) Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 33:2115–2119

    CAS  PubMed  Google Scholar 

  12. Nienhuis RL, Mandema E (1964) A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 23:302–305

    Article  CAS  PubMed  Google Scholar 

  13. Scott DL, Delamere JP, Jones LJ et al (1981) Significance of laminar antikeratin antibodies to rat oesophagus in rheumatoid arthritis. Ann Rheum Dis 40:267–271

    Article  CAS  PubMed  Google Scholar 

  14. Schellekens GA, de Jong BA, van den Hoogen FH et al (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273–281

    Article  CAS  PubMed  Google Scholar 

  15. Quinn MA, Gough AK, Green MJ et al (2006) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 45:478–480

    Article  CAS  Google Scholar 

  16. Silveira IG, Burlingame RW, von Muhlen CA et al (2007) Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 26:1883–1889

    Article  CAS  PubMed  Google Scholar 

  17. Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163

    Article  CAS  PubMed  Google Scholar 

  18. Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65:845–851

    Article  CAS  PubMed  Google Scholar 

  19. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709–715

    Article  PubMed  Google Scholar 

  20. Mimori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44:1122–1126

    Article  CAS  PubMed  Google Scholar 

  21. Abdel-Nasser AM, Mahmoud MH, El Mansoury TM, Osman AM (2008) Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis. Scand J Rheumatol 37(5):329–336

    Article  CAS  PubMed  Google Scholar 

  22. Symmons DP (2007) Classification criteria for rheumatoid arthritis—time to abandon rheumatoid factor? Rheumatology (Oxford) 46(5):725–726

    Article  CAS  Google Scholar 

  23. Visser H, le Cessie S, Vos K et al (2002) How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357–365

    Article  PubMed  Google Scholar 

  24. Carmona L, González-álvaro I, Balsa A et al (2003) Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 62:897–900

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Many thanks to Professor Yin Su and Dr. Rong Mu for their valuable ideas. Xiangyuan Liu made the same contribution as the first author. This work was partially supported by grant from the National Natural Science Foundation of China (No. 30772012).

Disclosures

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zhanguo Li.

Additional information

Xiangyuan Liu made the same contribution as the first author.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, J., Liu, X., Wang, Z. et al. Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis. Clin Rheumatol 29, 33–38 (2010). https://doi.org/10.1007/s10067-009-1296-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1296-7

Keywords

Navigation